CD4 and neoplasm: An in-depth analysis of CD4+ T cells infiltrating human melanoma specimens revealed the diverse targets of anti-tumor CD4+ TCRs, including MHC class II-restricted neoantigens and HLA class I-restricted TAAs (15).